Alternatives to DNABERT

Open-source, self-hosted AI research assistant for drug discovery — molecular property prediction, virtual screening and PK/PD modeling on your own hardware.

CURE-Bench is an open-source benchmark grading AI therapeutic decision-making and software-engineering reasoning at scale.

Open-source Python framework that assembles causal and mechanistic models from literature and biological databases.

Generative AI drug discovery suite spanning target ID, molecule design, biologics and clinical trial prediction.

All-in-human AI foundation models for precision neurology — vBx-1.0 predicts brain activity and therapy response from a blood draw.

Causal AI drug discovery pairing 20+ petabytes of cellular data with human genetics to find true disease targets

PepGLAD generates full-atom peptide structures and sequences together, conditioned on a target protein binding pocket, via geometric latent diffusion.

Cellbyte is the AI workspace where pharma Pricing & Market Access teams get source-linked HTA and pricing answers in minutes.

Lamin is a lineage-native open data platform and LaminDB library for traceable, multimodal biotech data — query, govern, and version

Thesis is building Darwin, a humanoid robot for the home, with in-home deployment targeted for early 2027.

Isomorphic Labs uses AI drug discovery models to design novel molecules and predict how candidate drugs will perform.

Owkin's K Pro is an autonomous AI scientist agent for biopharma R&D, turning multimodal patient data into drug discovery and clinical trial

Recursion OS pairs automated wet labs with AI models for AI drug discovery at up to 2 million weekly experiments.

Evotec is a life-science partner running AI-assisted drug discovery and Just–Evotec Biologics manufacturing.

Silico is Goodfire's interpretability agent for understanding and debugging the internals of your AI models.

Nimbus Therapeutics designs highly selective small-molecule drugs for oncology, immunology, and metabolic disease.

Atomwise APEX Protocol screens 10 billion compounds in under 30 seconds for small-molecule drug discovery

Generate Biomedicines uses generative biology to design AI protein therapeutics — antibodies, enzymes, and cytokines — and move them into

Oncology real-world evidence platform combining high-fidelity patient data with AI-assisted cancer research insights.

Iktos pairs generative AI with robotic lab automation to compress small-molecule drug discovery.

Renamed: Deep 6 AI was acquired by Tempus AI in March 2025 and its trial matching folded into Tempus.

Physics-based molecular simulation with AI for drug discovery and materials design.

Benchling unifies ELN, LIMS, and AI agents for biotech R&D in one cloud platform.

FDA-cleared AI for cancer pathology: prostate, breast, GI and pan-cancer detection on H&E slides, plus Virchow foundation models for research.

Quibim turns MRI, CT and PET scans into regulatory-cleared quantitative imaging biomarkers for prostate, brain, liver, breast and lung.

Google's umbrella health initiative: consumer health info, research tools like AlphaFold, and clinical AI research.

Tempus pairs tumor DNA/RNA sequencing with AI precision oncology analytics to surface treatment and trial matches

Iambic Therapeutics pairs Enchant v3 and NeuralPLexer AI drug discovery with weekly wet lab readouts and a clinical-stage pipeline.

AI protein engineering that optimizes binding, stability, activity, and expression across wet-lab rounds.

Cellino's AI-guided optical bioprocessing automates personalized cell therapy manufacturing on the Nebula™ platform.